Anorexiants Market 2024-2028: Size and Low safety and tolerability profile of anti-obesity drugs; growth driven by the Distribution Channel, Some of key Companies Positioned Strategically

The anorexiants market size by Distribution Channel (Hospital pharmacy, Retail pharmacy, and Online pharmacy) and Geography (North America, Europe, Asia, and Rest of World (ROW)), is forecast to increase by USD 1023.4 million. The market is expected to grow at a CAGR of   4.5% between 2024 and 2028.

• The obesity epidemic continues to escalate, leading to an increased demand for effective anti-obesity solutions. Anorexiants, a subset of anti-obesity drugs, offer significant weight loss benefits, but come with notable risks. New-generation anorexiants are recommended sparingly to adults due to safety concerns. These medications interfere with bodily processes, primarily suppressing appetite or increasing metabolism, to prevent weight gain. However, their use may result in adverse effects such as diarrhea, headaches, nausea, and vomiting. Severe side effects, including insomnia, elevated blood pressure, tremors, and blurred vision, can also occur. As a professional, it's crucial to acknowledge the potential benefits and risks associated with anorexiants when discussing this market.
• The anorexiants market refers to the pharmaceutical industry segment specializing in appetite suppressants. These medications are essential for managing weight loss treatments for individuals struggling with obesity and other related health conditions. Market growth is driven by increasing obesity rates worldwide, regulatory approvals for new anorectic drugs, and rising consumer awareness of weight management solutions. Companies are investing in research and development to produce safer and more effective anorexic agents, thereby expanding the market's potential.

Access the full report to know who are the other key countries segment-wise forecast and historic data

Some of the Key Companies:

• Bausch Health Companies Inc.
• Currax Pharmaceuticals LLC
• Elite Pharmaceuticals Inc.
• Epic Pharma LLC
• F. Hoffmann La Roche Ltd.
• Hi Tech Pharmaceuticals
• Intas Pharmaceuticals Ltd.
• Johnson and Johnson Services Inc.
• KVK Tech Inc.
• Lannett Co. Inc.
• Novartis AG
• Novo Nordisk AS
• Pfizer Inc.
• Recordati S.p.A
• Searchlight Pharma Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Virtus Nutrition LLC
• VIVUS LLC
• Zydus Lifesciences Ltd.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/